All In Biotech

Drug Trial Radar · NCT06617793

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Participants With Relapsing Multiple Sclerosis With Breakthrough Disease Activity During Previous Treatment With a Highly Efficacious Therapy

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Feb 24, 2025

Primary completion

Aug 7, 2030

Study completion Aug 7, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity during previous treatment with a highly efficacious therapy (BD-HET). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • rapcabtagene autoleucel (YTB323)Biological

    CAR-T cell suspension for intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 through Year 2

Locations

18 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nancy, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Córdoba, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Valencia, Spain

  • Novartis Investigative Site

    Bern, Switzerland

  • Novartis Investigative Site

    Lausanne, Switzerland

  • Novartis Investigative Site

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.